Pfizer to Discontinue Danuglipron’s Development Program for Chronic Weight Management
Shots:
- Pfizer has discontinued the development of danuglipron (PF-06882961) as a potential therapy for chronic weight management
- Danuglipron was evaluated in 2 P-I trials (NCT06567327 & NCT06568731), meeting key PK objectives & confirming formulation & dose with a potential for strong efficacy & tolerability in P-III. However, a case of drug-induced liver injury & recent regulatory input led to discontinuation of the development program
- Danuglipron’s (GLP-1 receptor agonist) clinical data will be presented at a future conference & published in a peer-reviewed journal
Ref: Pfizer | Image: Pfizer
Related News:- Pfizer Secures the EC’s Approval for Abrysvo (Respiratory Syncytial Virus Vaccine) for RSV Lower Respiratory Tract Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
